<p>Franck Morschhauser joins Ben Abbott of The Lancet to discuss the phase 3 EPCORE FL-1 study on epcoritamab, lenalidomide, and rituximab for relapsed or refractory follicular lymphoma, which is being presented at ASH 2025.</p>

Franck Morschhauser joins Ben Abbott of The Lancet to discuss the phase 3 EPCORE FL-1 study on epcoritamab, lenalidomide, and rituximab for relapsed or refractory follicular lymphoma, which is being presented at ASH 2025.

In conversation with... Franck Morschhauser

The Lancet (www.thelancet.com) is a weekly medical journal, renowned for the publication of high-quality peer-reviewed research and reviews from around the world. In the Podcasts our editors discuss journal highlights, including interviews with authors of key articles to provide context and insight to advancements in medicine and health worldwide.

Share In conversation with... Franck Morschhauser

Sign up to save your podcasts

In conversation with... Franck Morschhauser

In conversation with... Franck Morschhauser